The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...

Department of Medicine III – Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.

Global Regulatory and Scientific Policy, The Healthcare Business of Merck KGaA, Darmstadt, Germany. *Corresponding Author: Marén U. Koban, Global Regulatory Affairs, The Healthcare Business of Merck ...

Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and ...

The FDA approved pembrolizumab (Keytruda; Merck) with chemotherapy as a first-line treatment for advanced or metastatic malignant pleural mesothelioma (MPM) that cannot be removed with surgery. In ...

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...

The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...

CDK2 inhibitors have received some attention at the 2024 ESMO Congress, with one candidate, PF-07104091, showing combination potential with CDK4-selective blockade in HR–positive, HER2–negative breast ...

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.